How does the NHS realise the value of world class Digital Therapeutics?

March 24, 2018

Do you have questions about ‘Digital Therapeutics’?

  1. What is it?

  2. Are there any compelling examples of real world application?

  3. Is there any evidence to suggest they can improve health outcomes?

  4. What does ‘good’ look like?

  5. How do I embed clinically proven digital therapeutics into clinical practice?

  6. How do I commission this type of healthcare intervention?

  7. Is there sufficient evidence to give me the confidence to recommend or prescribe these ‘medicines’?

This invitation-only summit will bring together key decision makers from across the NHS, NICE, NIHR and PHE, with leading suppliers of digital therapeutic solutions. Delegates will gain a clear insight into the current evidence underpinning this cutting-edge technology. Delegates will have the opportunity to participate in discussions focussed on reaching a consensus on what good looks like for digital therapeutics. Delegates will also be able to contribute to the thinking currently driving the emerging work to create guidance for commissioners to support decision making.


Event Highlights

  • Hear directly from NHS England, NICE, NIHR on their vision for the future of digital therapeutics

  • Debate the role of clinical evidence in digital therapeutics assessment and commissioning

  • Influence the emerging thinking being led by NHS England and NICE to create guidance for commissioners to support better decision making

  • Engage with digital therapeutic companies from around the world with best in class clinical evidence to understand ‘what good could look like’

As seen in the IQVIA Institute for Human Data Science report, The Growing Value of Digital Health, the overall body of clinical evidence on app effectiveness has grown substantially and now includes 571 published studies. More than 27 use cases for Digital Health apps have at least one positive Randomized Controlled Trial (RCT) ranging from diabetes, to depression, to cancer. Based on this level of clinical value, the UK may conservatively save £2 billion in unnecessarily healthcare costs if these evidence based digital therapeutics are appropriately matched to target patients. The vast majority of these savings would be realized by the public sector.


Agenda for the day



We invite all key NHS decision makers and ecosystem participants to join us for this event.


Source :


Share on Facebook
Share on Twitter
Please reload

Please reload